Michael T Chang, MD
Otolaryngology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chang’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A152394 · Current
Licensed to practise in California · since 2017 · expires 2027-03-31 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$110,053
Medicare paid this office $110,053 for 166 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Biopsy or removal of nasal polyp or tissue using an endoscope | 39 | $20,328 | $339 |
| Diagnostic exam of nasal passages using an endoscope | 79 | $18,834 | $190 |
| New patient visit (45+ min) | 33 | $5,247 | $159 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 16 | $3,959 | $198 |
| Removal of nasal sinus tissue using an endoscope | 12 | $2,560 | $213 |
See all 16 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 39 | $20,328 | $339 |
| Diagnostic exam of nasal passages using an endoscope | 79 | $18,834 | $190 |
| New patient visit (45+ min) | 33 | $5,247 | $159 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 16 | $3,959 | $198 |
| Removal of nasal sinus tissue using an endoscope | 12 | $2,560 | $213 |
| Diagnostic exam of nasal passages using an endoscope | 41 | $2,484 | $54 |
| Long return visit (40+ min) | 13 | $2,420 | $173 |
| Short return visit (20+ min) | 21 | $2,035 | $88 |
| New patient visit (30+ min) | 20 | $2,019 | $101 |
| Return visit (30+ min) | 13 | $1,856 | $124 |
| New patient visit (45+ min) | 13 | $1,554 | $120 |
| Return visit (30+ min) | 13 | $1,139 | $88 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,023 | $73 |
| Short return visit (20+ min) | 13 | $773 | $55 |
| New patient visit (30+ min) | 12 | $759 | $63 |
| Short return visit | 11 | $672 | $56 |
Who their Medicare patients are
166 Original Medicare patients in 2024. Average age 72 · Under 65 7% · 85 and older 7% · Women 59% · Also on Medicaid 17% · Health risk score 1.45. Above the middle of the specialty; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 68% · Coronary heart disease 28% · Diabetes 26% · Chronic kidney disease 17% · Cancer 16% · Atrial fibrillation 16% · COPD 15% · Depression 14% · Heart failure 13% · Stroke 11%.
The office billed $982,790, Medicare allowed $140,130 and paid $110,053; for 572 services of 43 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 166 | 572 | 72 | 1.45 | $982,790 | $110,053 |
| 2023 | 146 | 309 | 72 | 1.37 | $406,159 | $45,064 |
| 2022 | 148 | 255 | 72 | 1.42 | $203,882 | $25,492 |
| 2021 | 35 | 56 | 69 | 2.02 | $66,527 | $7,069 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 34 | $6,920 | $182 |
| Diagnostic exam of nasal passages using an endoscope | 27 | $5,785 | $199 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 11 | $5,542 | $346 |
| Diagnostic exam of nasal passages using an endoscope | 74 | $2,676 | $35 |
| New patient visit (45+ min) | 15 | $2,361 | $157 |
| New patient visit (45+ min) | 14 | $1,679 | $120 |
2022: 3 services
| Biopsy or removal of nasal polyp or tissue using an endoscope | 29 | $9,666 | $182 |
| Diagnostic exam of nasal passages using an endoscope | 116 | $2,845 | $23 |
| Short return visit (20+ min) | 12 | $819 | $59 |
2021: 1 service
| Diagnostic exam of nasal passages using an endoscope | 18 | $432 | $24 |
Medicaid work
$1,030 in 2024
Medicaid paid $1,030 for 24 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 24 | $1,030 |
| 2024 | 24 | 1 | 12 | $1,030 |
| 2023 | 12 | 1 | 12 | $315 |
| 2022 | 12 | 1 | 12 | $215 |
See the largest Medicaid services in earlier years
2023
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 12 | $315 |
2022
| Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure) | 12 | $215 |
Drugs they prescribed that Part D paid
$23,206
Pharmacies billed $23,206 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
101 generic and fewer than 11 brand-name prescriptions · $23,206 in drug cost · 19 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ipratropium | 26 | $864 | $33 |
| Azelastine | 23 | $683 | $30 |
Year by year
| 2024 | 109 | 56 | None | None | $23,206 |
| 2023 | 162 | 81 | 7% (11) | 9% | $33,276 |
| 2022 | 186 | 92 | 9% (17) | 0% | $5,392 |
| 2021 | 64 | 37 | 28% (18) | None | $11,170 |
| 2020 | 59 | 50 | 75% (44) | None | $865 |
| 2019 | 34 | 21 | 56% (19) | None | $859 |
| 2018 | 19 | 16 | 84% (16) | None | $1,111 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Azelastine | 34 | $1,392 | $41 |
| Ipratropium | 34 | $948 | $28 |
| Mupirocin | 24 | $237 | $10 |
| Amoxicillin-Clavulanate Potass | 11 | $165 | $15 |
2022: 7 drugs
| Ipratropium | 31 | $1,479 | $48 |
| Azelastine | 14 | $833 | $60 |
| Fluticasone Propionate | 11 | $335 | $30 |
| Amoxicillin-Clavulanate Potass | 15 | $310 | $21 |
| Mupirocin | 24 | $254 | $11 |
| Hydrocodone-Acetaminophen | 14 | $69 | $5 |
| Prednisone | 11 | $33 | $3 |
2020: 2 drugs
| Oxycodone | 22 | $91 | $4 |
| Hydrocodone-Acetaminophen | 15 | $57 | $4 |
2019: 1 drug
| Hydrocodone-Acetaminophen | 12 | $43 | $4 |
Money from drug and device companies
$372 in 2025
| 2025 | 4 | 7 | None | $372 |
| 2024 | 1 | 3 | None | $183 |
| 2022 | 6 | 9 | None | $633 |
| 2021 | 2 | 3 | None | $75 |
| 2020 | 1 | 1 | None | $21 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Propel | $229 | 4 payments
|
| Integra LifeSciences | Acclarent Aera | $83 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $39 | 1 payment
|
| Stryker | Hemopore | $20 | 1 payment
|
See all 7 published payments
| Medtronic | Travel · 2025-10-13 | None | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-10 | Tezspire | $39 |
| Medtronic | Meals · 2025-10-07 | None | $39 |
| Medtronic | Meals · 2025-08-07 | Propel | $167 |
| Integra LifeSciences | Meals · 2025-08-01 | Acclarent Aera | $83 |
| Medtronic | Meals · 2025-02-14 | Stealthstation S8 Platform | $5 |
| Stryker | Meals · 2025-01-29 | Hemopore | $20 |
See earlier years (2024, 2022, 2021, 2020)
2024: $183
| Stryker | Core | $183 | 3 payments
|
2022: $633
| Stryker | Xpress Ent Dilation System | $197 | 4 payments
|
| Aerin Medical | None | $162 | 1 payment
|
| Medtronic | Propel | $136 | 1 payment
|
| GlaxoSmithKline | Nucala | $99 | 1 payment
|
| DePuy Synthes Sales | Trumatch | $24 | 1 payment
|
| Cook Medical | Hemospray | $15 | 1 payment
|
2021: $75
| Cook Medical | Hemospray | $54 | 2 payments
|
| Stryker | Xpress Ent Dilation System | $20 | 1 payment
|
2020: $21
| Medtronic USA | Fusion | $21 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1720432016
- Licence
- CA A152394California A152394: Current · expires 2027-03-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Otolaryngology (207Y00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2016-04-22
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 801 Welch Rd, Stanford, CA, 94305